Breast Cancer

Scientists from Dana-Farber Cancer Institute found that a compound that can reverse the function of innate immune system cells-to fight tumors rather than encourage growth-caused breast tumors in mice to shrink and withdraw from distant metastases.

Surgical oncologists can help reduce the risk of patients developing opioid dependence.

Breast conservation therapy is usually best for local treatment for stage II breast cancer-and biology, as well as stage, drives patient outcomes.

Despite breast tumors’ lower mutational loads than lung cancers and melanoma-cancers in which immunotherapy have shown particular promise-breast cancers are nevertheless immunogenic.

The United States Medicare Access and CHIP Reauthorization Act of 2015 quality- and payment-related provisions took effect January 1, 2017, and how oncologists comply this year will determine their payments in 2019.

Refining the American Joint Committee on Cancer breast cancer staging system to include molecular tumor markers will improve patient risk stratification and determination of prognosis.

Timing remains an important challenge for breast reconstruction in patients undergoing radiation therapy and surgery for breast cancer.

Recent findings have raised doubts about the promise of whole-brain radiation therapy against metastatic brain tumors for patients with advanced breast cancer.

Breast surgeons can and should provide genetic counseling to their patients because the need outstrips the availability of genetic counselors.

We spoke with breast imaging radiologist Dr. Elizabeth Morris on imaging vigilance for women at high risk of developing breast cancer.

A cost-effectiveness analysis found that 9 weeks of trastuzumab therapy is better than the more standard 12 months in patients with HER2-positive breast cancer, without loss of clinical efficacy.

Some women with breast cancer may survive longer if they consume soy-based foods, according to a new study.

Scientists have discovered that African American patients with triple-negative breast cancer who carry a specific biomarker, nKIFC1, experience a dismal prognosis.

Researchers at the University of Illinois and collaborators in China have found a way to tag and target elusive cancers with small-molecule sugars by hijacking a cancer cell’s own metabolism.

In patients with breast cancer with a recurrence score based on a 21-gene expression assay of 11 to 25, outcomes were similar whether chemotherapy was used or not.

Combining a genetically engineered epothilone analog known as utidelone with capecitabine significantly improved progression-free survival in women with metastatic breast cancer who were refractory to anthracycline and taxane regimens.

Relatively few clinically important therapeutic advances have occurred in the treatment of triple-negative breast cancer since the introduction of taxanes as adjuvant therapy over 20 years ago. However, this is rapidly changing due to a variety of conceptually important clinical trials and emerging new options.

We know that breast cancer represents a spectrum of diseases, with variation in prognosis, and that RT can range from highly complex treatments to the breast and regional lymph nodes, to complete avoidance of radiation.

To paraphrase a deep philosophical question: if an important, long-awaited phase III prospective randomized trial from Europe is published and no one pays attention, does it make a sound?

A phase I trial found that ONT-380 had a lower incidence of certain adverse events associated with this class of agent and notable anti-tumor activity in heavily pretreated metastatic HER2-positive breast cancer patients.

A large registry study found that certain breast cancer patients gain a significant survival benefit with breast conserving surgery plus radiation therapy compared with mastectomy.

Researchers at Johns Hopkins Kimmel Cancer Center have been studying the ability of a novel panel of cell-free DNA methylation markers to predict survival in women with metastatic breast cancer.

Residual cancer burden was found to be prognostic for long-term survival following neoadjuvant chemotherapy for three phenotypic subsets of breast cancer in a new single-institution study.

A secondary concern of breast cancer is the risk of the cancer cells spreading to the bones, causing severe pain and affecting quality of life. But a new study has identified how bones get damaged and researchers from Huntsman Cancer Institute at the University of Utah are developing a new drug to mitigate this problem.

Anxiety is common among partners of young breast cancer survivors, even several years after the diagnosis, according to a new analysis. Anxiety was correlated with the use of less constructive and more maladaptive coping strategies.